Skip to Content

Toremifene Approval Status

Toremifene is an investigational oral selective estrogen receptor modulator for the prevention of bone fractures in men with prostate cancer on androgen deprivation therapy.

In November 2009, GTx, Inc. announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for toremifene had not been approved.

Development Status and FDA Approval Process for toremifene

Nov  2, 2009GTx Receives Complete Response Letter from FDA for Toremifene 80 mg New Drug Application
Mar  5, 2009FDA Provides PDUFA Target Agency Action Date For GTx's Toremifene 80 mg NDA
Feb 18, 2009GTx Announces Toremifene 80 mg NDA Accepted for Review by FDA
Dec 30, 2008GTx Submits New Drug Application for Toremifene 80 mg for the Prevention of Bone Fractures in Men with Prostate Cancer on Androgen Deprivation Therapy

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.